ZT 002
Alternative Names: ZT-002Latest Information Update: 18 Sep 2024
Price :
$50 *
At a glance
- Originator QL Biopharmaceutical
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 12 Sep 2024 QL Biopharm plans a regulatory interaction with US FDA to advance the program outside China
- 09 Sep 2024 Updated efficacy and adverse events data from a phase Ic trial in Obesity presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)
- 03 Sep 2024 Phase-II clinical trials in Obesity in China (SC)